Regulation - Nephrology and Hepatology, Astellas Pharma

Filter

Popular Filters

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

04-01-2012

US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib

Company Spotlight

ImmunoGen

ImmunoGen

Back to top